Japan provided the antiviral drug Avigan to the United Kingdom on May 15, 2024 [1].
The shipment follows a request from British authorities after a suspected cluster of hantavirus infections was identified on a cruise ship. Because hantavirus can cause severe respiratory distress and systemic failure, the rapid deployment of potential treatments is critical for containing outbreaks in confined environments.
Kenichiro Ueno, the Minister of Health, Labour and Welfare, announced the delivery of the favipiravir-based medication. The drug was sent from Japan to the UK to assist in managing the suspected medical emergency [1].
Ueno said the decision to provide Avigan was based on previous research. "Avigan has shown results in past animal experiments that increase the survival rate after infection with hantavirus," Ueno said [1].
Despite the promising results in animal models, the minister clarified that the drug's application in this specific context is not based on human clinical success. Ueno said, "There are no cases of administration to people infected with hantavirus" [1].
The use of the drug in the UK represents an attempt to apply laboratory findings to a real-world crisis. The Japanese government's decision to supply the medication underscores a cooperative effort to mitigate the risks associated with rare, but potentially deadly, viral clusters.
“"Avigan has shown results in past animal experiments that increase the survival rate after infection with hantavirus"”
The deployment of Avigan in the UK highlights a gap in established human treatments for hantavirus. By relying on animal study data, health officials are utilizing an experimental approach to prevent fatalities in a high-risk cruise ship environment, though the lack of human clinical trials means the efficacy remains unproven in people.
